WPD Pharmaceuticals Inc.

CNSX:WBIO Stock Report

Market Cap: CA$579.9k

WPD Pharmaceuticals Valuation

Is WBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of WBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate WBIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate WBIO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for WBIO?

Key metric: As WBIO is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for WBIO. This is calculated by dividing WBIO's market cap by their current book value.
What is WBIO's PB Ratio?
PB Ratio-0.9x
Book-CA$675.64k
Market CapCA$579.94k

Price to Book Ratio vs Peers

How does WBIO's PB Ratio compare to its peers?

The above table shows the PB ratio for WBIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average12.6x
CURE.X Biocure Technology
0.07xn/aCA$313.3k
NAV NAVCO Pharmaceuticals
43.1xn/aCA$856.0k
ENBI Entheon Biomedical
5.4xn/aCA$1.2m
VXL Vaxil Bio
1.7xn/aCA$1.4m
WBIO WPD Pharmaceuticals
n/an/aCA$579.9k

Price-To-Book vs Peers: WBIO has negative equity and a Price-To-Book Ratio (-0.9x) compared to the peer average (12.6x).

Price to Book Ratio vs Industry

How does WBIO's PB Ratio compare vs other companies in the CA Biotechs Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
QPT Quest PharmaTech
0.3xn/aUS$4.82m
CURE.X Biocure Technology
0.07xn/aUS$223.42k
No more companies available in this PB range
WBIO is unprofitableIndustry Avg. 3.1xNo. of Companies3PB01.22.43.64.86+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: WBIO has negative equity and a Price-To-Book Ratio (-0.9x) compared to the Canadian Biotechs industry average (3.1x).

Price to Book Ratio vs Fair Ratio

What is WBIO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

WBIO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-0.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate WBIO's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Cresco Labs

CA$744.9m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CL

CA$1.72

7D

3.0%

1Y

-25.2%

Decibel Cannabis

CA$27.7m

An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.

DB

CA$0.065

7D

0%

1Y

-50.0%

Theratechnologies

CA$80.0m

A biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe.

TH

CA$1.68

7D

-1.2%

1Y

-25.3%